- Home
- MCGA vs PROF Comparison
MCGA vs PROF Comparison
Compare MCGA & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCGA | PROF |
|---|---|---|
| Founded | 2025 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.0M | 263.8M |
| IPO Year | 2025 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MCGA | PROF |
|---|---|---|
| Price | $10.35 | $6.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 111.5K | 95.7K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | N/A | $92.40 |
| Revenue Next Year | N/A | $64.10 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $10.09 | $3.92 |
| 52 Week High | $10.83 | $8.95 |
Technical Indicators
Market Signals| Indicator | MCGA | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 68.41 | 46.56 |
| Support Level | $10.10 | $6.47 |
| Resistance Level | N/A | $7.04 |
| Average True Range (ATR) | 0.01 | 0.32 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 83.33 | 37.78 |
Price Performance
Historical ComparisonAbout MCGA Yorkville Acquisition Corp. Class A Ordinary Share
Yorkville Acquisition Corp is a blank check company.
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.